Abstracts tagged "hyaluronate and osteoarthritis"

Abstract Number: 1198 • 2017 ACR/ARHP Annual Meeting
Intra-Articular Hyaluronic Acid Delay to Total Knee Arthroplasty By Number of Injection Courses Received: Analysis of an Administrative Database
Andrew Concoff¹, Faizan Niazi², Peter Shaw² and Jeffrey Rosen³, ¹Rheumatology, St. Jude Medical Center, Fullerton, CA, ²Ferring Pharmaceuticals Inc., Parsippany, NJ, ³Department of Orthopaedics & Rehabilitation, New York Presbyterian Queens; Department of Clinical Orthopaedic Surgery, Weill Medical College of Cornell University, New York, NY, New York, NY
Background/Purpose: Total knee arthroplasty (TKA) is the standard surgical treatment for patients with osteoarthritis (OA) that no longer experience symptom relief from conservative or pharmacologic…
Abstract Number: 1199 • 2017 ACR/ARHP Annual Meeting
Costs Associated with Osteoarthritis Care Using Intra-Articular Hyaluronic Acid: Analysis of an Administrative Database
Andrew Concoff¹, Faizan Niazi², Peter Shaw² and Jeffrey Rosen³, ¹Rheumatology, St. Jude Medical Center, Fullerton, CA, ²Ferring Pharmaceuticals Inc., Parsippany, NJ, ³Department of Orthopaedics & Rehabilitation, New York Presbyterian Queens; Department of Clinical Orthopaedic Surgery, Weill Medical College of Cornell University, New York, NY, New York, NY
Background/Purpose: Many treatment options are available for the management of knee osteoarthritis (OA). The need for non-operative management is motivated by the large costs associated…
Abstract Number: 315 • 2016 ACR/ARHP Annual Meeting
Hip Inflammation MRI Scoring System (HIMRISS) to Predict Response to Hyaluronic Acid (HAnox-M-XL) Injection in Hip Osteoarthritis
Nicolas Deseyne¹, Damien Loeuille², Thierry Conrozier³, Ulrich Weber⁴, Jacob Jaremko⁵, Henri Lellouche⁶, Bernard Maillet⁷, Joel Paschke⁸, Jonathan Epstein⁹ and Walter P. Maksymowych¹⁰, ¹Department of Rheumatology, CHRU Vandoeuvre les Nancy,, Vandoeuvre, France, ²Rheumatology, CHRU Nancy, Vandoeuvre les Nancy, France, ³Department of Rheumatology, North Hospital Franche-Comté, Belfort, France, ⁴Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Department of Rheumatology, Lariboisière Hospital, Paris, France, Paris, France, ⁷Department of Rheumatology, Clinique Saint Odilon, Moulins, France, Moulins, France, ⁸CaRE Arthritis, Edmonton, AB, Canada, ⁹CEC-Inserm CIE6, Epidemiology and Clinical Evaluations Department, CHRU Vandoeuvre les Nancy, France, Vandoeuvre Les Nancy, France, ¹⁰Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: To assess predictors of response, according to hip MRI inflammatory scoring system (HIMRISS), in a sample of patients with hip osteoarthritis (OA) treated by…
Abstract Number: 310 • 2015 ACR/ARHP Annual Meeting
Hyaluronic Acid Injections in Knee Osteoarthritis Patients Are Associated with Delay to Knee Arthroplasty
Kevin Ong¹, Allen Anderson², Edmund Lau³, Faizan Niazi⁴, Anke Fierlinger⁴, Steven Kurtz¹ and Roy Altman⁵, ¹Exponent, Inc., Philadelphia, PA, ²Tennessee Orthopaedic Alliance, Powderly, KY, ³Exponent, Inc., Menlo Park, CA, ⁴Ferring Pharmaceuticals, Inc., Parsippany, NJ, ⁵David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: Although only few nonoperative treatment options for knee osteoarthritis (OA) are available, there continues to be debate about the effectiveness of hyaluronic acid (HA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].